The technology behind our CalRexin™ calcitonin receptor antibody
Our Technology
Our technology is based on the only available monoclonal antibody against a definable and extracellular linear target of the human calcitonin receptor (CTR). Accumulation of the CTR on the cell surface is an event associated with cell stress and Programmed Cell Death (PCD) – this is one of our key discoveries. The extracellular target epitope of our antibody makes it a suitable target for the delivery of therapeutic or diagnostic substances to reach diseased cells and tissues.
Our unique antibody enables the development of novel conjugates with applications in research and imaging, diagnostics and therapeutic interventions.
Patents
PCT/AU2008/001435; WO 2009/039584, Patent No 2203747. Diagnosis and treatment of diseased and damaged tissue.
Int PCT/AU2014/001081 Marker of cell death.